Scientific Industries, Inc. · OTC:SCND
Scientific Industries — Investor Presentation (September 2024)
19 slides from Scientific Industries's investor presentation, September 2024
Slide 1: Investor Presentation September 2024
INVESTOR PRESENTATION September 2024 PRIVATE AND CONFIDENTIAL • ALL RIGHTS RESERVED PRIVATE AND CONFIDENTIAL • ALL RIGHTS RESERVED
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements within the meaning of the federal securities laws. All statements, other than statements of historical facts, included in this presentation that address activities, events or developments that Scientific Industries, Inc. and its subsid
Slide 3: SCND is a Life-Science Tools Enterprise poised for Breakout
SCND is a Life-Science Tools Enterprise poised for Breakout Scientific Industries is a Life Science Tools Company comprised of two businesses; its legacy base business, characterized by stable revenues, growth, and earnings, and its SBI business, we expect to deliver outsized growth in the coming ye
Slide 4: Leadership and Board Track Record of Proven Success in Life Sciences
Scientific Industries’ Leadership and Board has a Track Record of Proven Success in the Life Sciences Business. Helena Santos John Moore Reginald Averilla Daniel Gruenes SCND President & CEO SCND Chairman SCND CFO SBI President & CEO John Nicols Chris Cox Dr. Juergen Schumacher Michael Blechman SBI
Slide 5: Profitable legacy business supporting high growth bioprocessing division
Profitable legacy business supporting high growth, revolutionary bioprocessing division. Founded in 1954 Acquired in 2014 Acquired in 2021 The World Enabling Digitally Enabling the Synthetic Biology Leader in Simplified Pharmacy with Revolution via Digitally Vortex Mixing Scales & Pill Counters Simp
Slide 6: Profitable & Proven Base Business
Profitable & Proven Base Business
Slide 7: Positioned to achieve significant operating leverage
Scientific Industries is positioned to achieve significant operating leverage driven by the strong growth potential of its bioprocessing operations.
Slide 8: SBI addresses a $2B Market in Synthetic Biology with DOTS Technology
SBI addresses a $2B Market in Synthetic Biology with its DOTS Technology platform for Digitally Simplified Bioprocessing. b>, Maastricht <q University aqui Ss b SCIENTIFIC Karolinska BIOPROCESSING Institutet ‘s ' pi . ' lppiess sereaiie Digitally Simplified Bioprocessing. Industry Association Daniel
Slide 9: SBI addresses a $2B Market; iPhone analogy
SBI In addresses 2007, a $2B the iPhone Market(1) an transformed in entire Synthetic Biology industry by bringing by merging various capabilities of technologies established into solutions a single, small, to the affordable andmost ubiquitous easy-to-use vessel. device.
Slide 10: The iPhone analogy: merging technologies into a single device
It’s2007, In beenthe done iPhone before: transformed in 2007, theaniPhone entire transformed industry by merging it’s fieldvarious by merging established technologiestechnologies into a single,into a small, small, affordable affordable and easy-to-use and easy-to-use device. device. Simplicity Sensi
Slide 11: Bioprocess development costs $3 Million and takes around 3 Years
Due to the lack of affordable and easy-to-use technologies, the average bioprocess development costs $3 Million and takes around 3 Years(2).
Slide 12: DOTS Technology enables fermenter-like experiments in shake flasks
SBI’s DOTS Technology enables Fermenter-like experiments in shake flasks and helps customers to bring down costs and development times.
Slide 13: The DOTS Technology Platform components
The DOTS Technology Platform consists of 4 components and a first full version was launched in April 2024. Shake Flask Simple Cultivation Vessel VA DOTS Software Hi ill tl I: Real-Time Data Insights, LU i Analysis & Visualization it Feeding System Feedback-controlled, Automated Addition of Liquids D
Slide 14: DOTS investments pay off within a year
Case study shows that investments into DOTS components pay off within a year, due to significant savings in materials and labor hours.
Slide 15: DOTS platform launched and sees traction
The DOTS platform has been successfully launched and already sees traction and highlights commercial potential.
Slide 16: All Puzzle Pieces in Hand to Unlock the Market
We have all Puzzle Pieces in Hand to Unlock the Market of Digitally Simplified Bioprocessing – Shaping the Future of Biotechnology.
Slide 17: Capitalization Snapshot
Capitalization Snapshot As of June 30, 2024 As of June 30, 2024 Balance Sheet Shares Outstanding 10,503,599 Debt $0 Options 1,766,547 WAEP $6.17 Cash & Cash Equivalents(9) $3,855,600 Warrants 8,232,510 WAEP $3.50
Slide 18: Thank You
Thank You Get in Contact: John Moore: jmoore@scientificbio.com Helena Santos: hsantos@scientificindustries.com Daniel Grünes: daniel.gruenes@aquila-biolabs.de Reginald Averilla: raverilla@scientificindustries.com INVESTOR PRESENTATION September 2024 PRIVATE AND CONFIDENTIAL • ALL RIGHTS RESERVED PRI
Slide 19: References
References (1) Market size was estimated based on two market reports describing the global Small-Scale Bioreactor Market: a) “Small-Scale Bioreactors Market 2023-2030”, Grand View Research, 2022, Report ID GVR-4-68040-046-5, https://www.grandviewresearch.com/industry-analysis/small-scale-bioreactors
Scientific Industries — Investor Presentation (September 2024) on 6ix